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Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJP, Messig M, Breazna A, Pedersen TRCardiovascular Event Reduction Versus New-Onset Diabetes During
Atorvastatin Therapy: Effect of Baseline Risk Factors for Diabetes.
J Am Coll Cardiol 2013;61:148–52.
Page 149, Methods section, 2nd paragraph: “FBG was measured at each 6-month visit in both TNT and
IDEAL trials.”
should have read:
“In the TNT trial FBG was measured at randomization and each annual visit. The IDEAL protocol mandated
FBG measurements only at randomization and the end-of-study visit. Some investigators collected FBG at
additional time-points and that data was included in our analysis.”
The authors apologize for this error.http://dx.doi.org/10.1016/j.jacc.2014.09.002CORRECTION
Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, Morais J, Verheugt FW,
De Caterina RAspirin Therapy in Primary Cardiovascular Disease Prevention:
A Position Paper of the European Society of Cardiology Working
Group on Thrombosis.
J Am Coll Cardiol 2014;64:319–27.
In the section ‘Ongoing Studies’, on page 323, the following sentence was printed incorrectly:
“Most aspirin trials for primary CVD prevention have enrolled individuals at low cardiovascular risk, with
estimated coronary event rates <1% per person-years. To ﬁll a missing gap, 5 ongoing RCTs are investigating
the safety and efﬁcacy of 100 mg aspirin daily versus placebo (or vs. no aspirin) in more than 60,000 men and
women at a higher level of cardiovascular risk, that is, without known CVD but with estimated rates of coro-
nary events of 1% to 2% per person-years (or of total cardiovascular events w3 per person-years).”
It should read as follows:
“Most aspirin trials for primary CVD prevention have enrolled individuals at low cardiovascular risk, with
estimated coronary event rates <1 per 100 person-years. To ﬁll a missing gap, 5 ongoing RCTs are investigating
the safety and efﬁcacy of 100 mg aspirin daily versus placebo (or vs. no aspirin) in more than 60,000 men and
women at a higher level of cardiovascular risk, that is, without known CVD but with estimated rates of coro-
nary events of 1 to 2 per 100 person-years (or of total cardiovascular events w3 per 100 person-years).”
The authors apologize for this error.http://dx.doi.org/10.1016/j.jacc.2014.09.020
